Skip to main content
Clinical Trials/CTRI/2019/01/017326
CTRI/2019/01/017326
Not yet recruiting
未知

Short course steroid as add-on drug in treatment of chronic migraine- randomised placebo controlled study.

ational Institute of Mental Health and NeuroSciences0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
ational Institute of Mental Health and NeuroSciences
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
ational Institute of Mental Health and NeuroSciences

Eligibility Criteria

Inclusion Criteria

  • Chronic migraine patients meeting the criteria according to ICHD\-3 (2013\) on prophylaxis for a period of at least 3months.

Exclusion Criteria

  • \-Medical conditions that increase the risk of steroid administration like\-Diabetes Mellitus (operationally defined as FBS \>140; PPBS \>200mg/dl), Impaired glucose tolerance (postprandial glucose levels of 140 to 199 mg per dL), Impaired fasting glucose (glucose levels of 100 to 125 mg per dL in fasting patients), Active infections, Hypertension( \>140/90mmHg),Chronic co\-morbidities that might be affected by steroids or would make changes in the clinical or biochemical values that would likely unmask the blinding. Diagnosis of secondary headache, Complicated migraine, Beck Depression Inventory (BDI) \>24 (moderate depression)

Outcomes

Primary Outcomes

Not specified

Similar Trials